Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Identifieur interne : 003477 ( Main/Exploration ); précédent : 003476; suivant : 003478Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Auteurs : Maria Buti [Espagne] ; Kosh Agarwal [Royaume-Uni] ; Yves Horsmans [Belgique] ; William Sievert [Australie] ; Ewa Janczewska [Pologne] ; Stefan Zeuzem [Allemagne] ; Lisa Nyberg [États-Unis] ; Robert S. Brown [États-Unis] ; Christophe Hézode [France] ; Mario Rizzetto [Italie] ; Raymundo Paraná [Brésil] ; Sandra De Meyer [Belgique] ; Ralph De Masi [États-Unis] ; Donghan Luo [États-Unis] ; Kirk Bertelsen [États-Unis] ; James Witek [États-Unis]Source :
- Gastroenterology [ 1528-0012 ] ; 2014.
Descripteurs français
- KwdFr :
- ARN viral (sang), Adulte, Adulte d'âge moyen, Antiviraux (administration et posologie), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Association de médicaments, Calendrier d'administration des médicaments, Céphalée (épidémiologie), Fatigue (épidémiologie), Femelle, Génotype, Hepacivirus (génétique), Humains, Hépatite C chronique (sang), Hépatite C chronique (traitement médicamenteux), Incidence, Interféron alpha (effets indésirables), Interféron alpha (usage thérapeutique), Mâle, Nausée (épidémiologie), Oligopeptides (administration et posologie), Oligopeptides (effets indésirables), Oligopeptides (usage thérapeutique), Polyéthylène glycols (effets indésirables), Polyéthylène glycols (usage thérapeutique), Protéines recombinantes (effets indésirables), Protéines recombinantes (usage thérapeutique), Relation dose-effet des médicaments, Ribavirine (effets indésirables), Ribavirine (usage thérapeutique), Résultat thérapeutique.
- MESH :
- administration et posologie : Antiviraux, Oligopeptides.
- effets indésirables : Antiviraux, Interféron alpha, Oligopeptides, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- génétique : Hepacivirus.
- sang : ARN viral, Hépatite C chronique.
- traitement médicamenteux : Hépatite C chronique.
- usage thérapeutique : Antiviraux, Interféron alpha, Oligopeptides, Polyéthylène glycols, Protéines recombinantes, Ribavirine.
- épidémiologie : Céphalée, Fatigue, Nausée.
- Adulte, Adulte d'âge moyen, Association de médicaments, Calendrier d'administration des médicaments, Femelle, Génotype, Humains, Incidence, Mâle, Relation dose-effet des médicaments, Résultat thérapeutique.
English descriptors
- KwdEn :
- Adult, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Fatigue (epidemiology), Female, Genotype, Headache (epidemiology), Hepacivirus (genetics), Hepatitis C, Chronic (blood), Hepatitis C, Chronic (drug therapy), Humans, Incidence, Interferon-alpha (adverse effects), Interferon-alpha (therapeutic use), Male, Middle Aged, Nausea (epidemiology), Oligopeptides (administration & dosage), Oligopeptides (adverse effects), Oligopeptides (therapeutic use), Polyethylene Glycols (adverse effects), Polyethylene Glycols (therapeutic use), RNA, Viral (blood), Recombinant Proteins (adverse effects), Recombinant Proteins (therapeutic use), Ribavirin (adverse effects), Ribavirin (therapeutic use), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Oligopeptides.
- chemical , adverse effects : Antiviral Agents, Interferon-alpha, Oligopeptides, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , blood : RNA, Viral.
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha, Oligopeptides, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- blood : Hepatitis C, Chronic.
- drug therapy : Hepatitis C, Chronic.
- epidemiology : Fatigue, Headache, Nausea.
- genetics : Hepacivirus.
- Adult, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Genotype, Humans, Incidence, Male, Middle Aged, Treatment Outcome.
Abstract
We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis.
DOI: 10.1053/j.gastro.2013.11.047
PubMed: 24316262
Affiliations:
- Allemagne, Australie, Belgique, Brésil, Espagne, France, Italie, Pologne, Royaume-Uni, États-Unis
- Angleterre, Bahia, Californie, Catalogne, District de Darmstadt, Hesse (Land), New Jersey, Piémont, Région de Bruxelles-Capitale, Victoria (État), État de New York, Île-de-France
- Barcelone, Bruxelles, Créteil, Francfort-sur-le-Main, Melbourne, Turin
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003895
- to stream PubMed, to step Curation: 003780
- to stream PubMed, to step Checkpoint: 003780
- to stream Ncbi, to step Merge: 001635
- to stream Ncbi, to step Curation: 001635
- to stream Ncbi, to step Checkpoint: 001635
- to stream Main, to step Merge: 003493
- to stream Main, to step Curation: 003477
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.</title><author><name sortKey="Buti, Maria" sort="Buti, Maria" uniqKey="Buti M" first="Maria" last="Buti">Maria Buti</name><affiliation wicri:level="3"><nlm:affiliation>Liver Unit, Department of Internal Medicine, Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain. Electronic address: mbuti@vhebron.net.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Liver Unit, Department of Internal Medicine, Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Agarwal, Kosh" sort="Agarwal, Kosh" uniqKey="Agarwal K" first="Kosh" last="Agarwal">Kosh Agarwal</name><affiliation wicri:level="2"><nlm:affiliation>Institute of Liver Studies, Kings College Hospital, London, England.</nlm:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Institute of Liver Studies, Kings College Hospital, London</wicri:cityArea></affiliation></author><author><name sortKey="Horsmans, Yves" sort="Horsmans, Yves" uniqKey="Horsmans Y" first="Yves" last="Horsmans">Yves Horsmans</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Pharmacology Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Clinical Pharmacology Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Sievert, William" sort="Sievert, William" uniqKey="Sievert W" first="William" last="Sievert">William Sievert</name><affiliation wicri:level="3"><nlm:affiliation>Gastroenterology and Hepatology Unit, Monash Medical Centre and Monash University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Gastroenterology and Hepatology Unit, Monash Medical Centre and Monash University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Janczewska, Ewa" sort="Janczewska, Ewa" uniqKey="Janczewska E" first="Ewa" last="Janczewska">Ewa Janczewska</name><affiliation wicri:level="1"><nlm:affiliation>Outpatients Clinic for Hepatology, Outpatients Clinic for Hepatology, ID Clinic, Myslowice, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Outpatients Clinic for Hepatology, Outpatients Clinic for Hepatology, ID Clinic, Myslowice</wicri:regionArea><wicri:noRegion>Myslowice</wicri:noRegion></affiliation></author><author><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine I, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Medicine I, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Nyberg, Lisa" sort="Nyberg, Lisa" uniqKey="Nyberg L" first="Lisa" last="Nyberg">Lisa Nyberg</name><affiliation wicri:level="2"><nlm:affiliation>Hepatology Research Department, Kaiser Permanente, San Diego, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Hepatology Research Department, Kaiser Permanente, San Diego</wicri:cityArea></affiliation></author><author><name sortKey="Brown, Robert S" sort="Brown, Robert S" uniqKey="Brown R" first="Robert S" last="Brown">Robert S. Brown</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hepatology and Gastroenterology, Columbia University College of Physicians and Surgeons, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Hepatology and Gastroenterology, Columbia University College of Physicians and Surgeons, New York</wicri:cityArea></affiliation></author><author><name sortKey="Hezode, Christophe" sort="Hezode, Christophe" uniqKey="Hezode C" first="Christophe" last="Hézode">Christophe Hézode</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Créteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Rizzetto, Mario" sort="Rizzetto, Mario" uniqKey="Rizzetto M" first="Mario" last="Rizzetto">Mario Rizzetto</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hepatology and Gastroenterology, University of Torino, Torino, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hepatology and Gastroenterology, University of Torino, Torino</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="Parana, Raymundo" sort="Parana, Raymundo" uniqKey="Parana R" first="Raymundo" last="Paraná">Raymundo Paraná</name><affiliation wicri:level="2"><nlm:affiliation>Gastro-Hepatology Unit, Medical School, Federal University of Bahia, Bahia, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Gastro-Hepatology Unit, Medical School, Federal University of Bahia, Bahia</wicri:regionArea><placeName><region type="state">Bahia</region></placeName></affiliation></author><author><name sortKey="De Meyer, Sandra" sort="De Meyer, Sandra" uniqKey="De Meyer S" first="Sandra" last="De Meyer">Sandra De Meyer</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="De Masi, Ralph" sort="De Masi, Ralph" uniqKey="De Masi R" first="Ralph" last="De Masi">Ralph De Masi</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development LLC, Titusville, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Janssen Research & Development LLC, Titusville</wicri:cityArea></affiliation></author><author><name sortKey="Luo, Donghan" sort="Luo, Donghan" uniqKey="Luo D" first="Donghan" last="Luo">Donghan Luo</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development LLC, Titusville, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Janssen Research & Development LLC, Titusville</wicri:cityArea></affiliation></author><author><name sortKey="Bertelsen, Kirk" sort="Bertelsen, Kirk" uniqKey="Bertelsen K" first="Kirk" last="Bertelsen">Kirk Bertelsen</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development LLC, Titusville, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Janssen Research & Development LLC, Titusville</wicri:cityArea></affiliation></author><author><name sortKey="Witek, James" sort="Witek, James" uniqKey="Witek J" first="James" last="Witek">James Witek</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development LLC, Titusville, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Janssen Research & Development LLC, Titusville</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24316262</idno><idno type="pmid">24316262</idno><idno type="doi">10.1053/j.gastro.2013.11.047</idno><idno type="wicri:Area/PubMed/Corpus">003895</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003895</idno><idno type="wicri:Area/PubMed/Curation">003780</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003780</idno><idno type="wicri:Area/PubMed/Checkpoint">003780</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003780</idno><idno type="wicri:Area/Ncbi/Merge">001635</idno><idno type="wicri:Area/Ncbi/Curation">001635</idno><idno type="wicri:Area/Ncbi/Checkpoint">001635</idno><idno type="wicri:Area/Main/Merge">003493</idno><idno type="wicri:Area/Main/Curation">003477</idno><idno type="wicri:Area/Main/Exploration">003477</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.</title><author><name sortKey="Buti, Maria" sort="Buti, Maria" uniqKey="Buti M" first="Maria" last="Buti">Maria Buti</name><affiliation wicri:level="3"><nlm:affiliation>Liver Unit, Department of Internal Medicine, Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain. Electronic address: mbuti@vhebron.net.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Liver Unit, Department of Internal Medicine, Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Agarwal, Kosh" sort="Agarwal, Kosh" uniqKey="Agarwal K" first="Kosh" last="Agarwal">Kosh Agarwal</name><affiliation wicri:level="2"><nlm:affiliation>Institute of Liver Studies, Kings College Hospital, London, England.</nlm:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>Institute of Liver Studies, Kings College Hospital, London</wicri:cityArea></affiliation></author><author><name sortKey="Horsmans, Yves" sort="Horsmans, Yves" uniqKey="Horsmans Y" first="Yves" last="Horsmans">Yves Horsmans</name><affiliation wicri:level="3"><nlm:affiliation>Clinical Pharmacology Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Clinical Pharmacology Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Sievert, William" sort="Sievert, William" uniqKey="Sievert W" first="William" last="Sievert">William Sievert</name><affiliation wicri:level="3"><nlm:affiliation>Gastroenterology and Hepatology Unit, Monash Medical Centre and Monash University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Gastroenterology and Hepatology Unit, Monash Medical Centre and Monash University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Janczewska, Ewa" sort="Janczewska, Ewa" uniqKey="Janczewska E" first="Ewa" last="Janczewska">Ewa Janczewska</name><affiliation wicri:level="1"><nlm:affiliation>Outpatients Clinic for Hepatology, Outpatients Clinic for Hepatology, ID Clinic, Myslowice, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Outpatients Clinic for Hepatology, Outpatients Clinic for Hepatology, ID Clinic, Myslowice</wicri:regionArea><wicri:noRegion>Myslowice</wicri:noRegion></affiliation></author><author><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine I, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Medicine I, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation></author><author><name sortKey="Nyberg, Lisa" sort="Nyberg, Lisa" uniqKey="Nyberg L" first="Lisa" last="Nyberg">Lisa Nyberg</name><affiliation wicri:level="2"><nlm:affiliation>Hepatology Research Department, Kaiser Permanente, San Diego, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Hepatology Research Department, Kaiser Permanente, San Diego</wicri:cityArea></affiliation></author><author><name sortKey="Brown, Robert S" sort="Brown, Robert S" uniqKey="Brown R" first="Robert S" last="Brown">Robert S. Brown</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hepatology and Gastroenterology, Columbia University College of Physicians and Surgeons, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Hepatology and Gastroenterology, Columbia University College of Physicians and Surgeons, New York</wicri:cityArea></affiliation></author><author><name sortKey="Hezode, Christophe" sort="Hezode, Christophe" uniqKey="Hezode C" first="Christophe" last="Hézode">Christophe Hézode</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Créteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Rizzetto, Mario" sort="Rizzetto, Mario" uniqKey="Rizzetto M" first="Mario" last="Rizzetto">Mario Rizzetto</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hepatology and Gastroenterology, University of Torino, Torino, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hepatology and Gastroenterology, University of Torino, Torino</wicri:regionArea><placeName><settlement type="city">Turin</settlement><region type="région" nuts="2">Piémont</region></placeName></affiliation></author><author><name sortKey="Parana, Raymundo" sort="Parana, Raymundo" uniqKey="Parana R" first="Raymundo" last="Paraná">Raymundo Paraná</name><affiliation wicri:level="2"><nlm:affiliation>Gastro-Hepatology Unit, Medical School, Federal University of Bahia, Bahia, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Gastro-Hepatology Unit, Medical School, Federal University of Bahia, Bahia</wicri:regionArea><placeName><region type="state">Bahia</region></placeName></affiliation></author><author><name sortKey="De Meyer, Sandra" sort="De Meyer, Sandra" uniqKey="De Meyer S" first="Sandra" last="De Meyer">Sandra De Meyer</name><affiliation wicri:level="1"><nlm:affiliation>Janssen Infectious Diseases BVBA, Beerse, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Janssen Infectious Diseases BVBA, Beerse</wicri:regionArea><wicri:noRegion>Beerse</wicri:noRegion></affiliation></author><author><name sortKey="De Masi, Ralph" sort="De Masi, Ralph" uniqKey="De Masi R" first="Ralph" last="De Masi">Ralph De Masi</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development LLC, Titusville, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Janssen Research & Development LLC, Titusville</wicri:cityArea></affiliation></author><author><name sortKey="Luo, Donghan" sort="Luo, Donghan" uniqKey="Luo D" first="Donghan" last="Luo">Donghan Luo</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development LLC, Titusville, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Janssen Research & Development LLC, Titusville</wicri:cityArea></affiliation></author><author><name sortKey="Bertelsen, Kirk" sort="Bertelsen, Kirk" uniqKey="Bertelsen K" first="Kirk" last="Bertelsen">Kirk Bertelsen</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development LLC, Titusville, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Janssen Research & Development LLC, Titusville</wicri:cityArea></affiliation></author><author><name sortKey="Witek, James" sort="Witek, James" uniqKey="Witek J" first="James" last="Witek">James Witek</name><affiliation wicri:level="2"><nlm:affiliation>Janssen Research & Development LLC, Titusville, New Jersey.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Janssen Research & Development LLC, Titusville</wicri:cityArea></affiliation></author></analytic><series><title level="j">Gastroenterology</title><idno type="eISSN">1528-0012</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Fatigue (epidemiology)</term><term>Female</term><term>Genotype</term><term>Headache (epidemiology)</term><term>Hepacivirus (genetics)</term><term>Hepatitis C, Chronic (blood)</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Humans</term><term>Incidence</term><term>Interferon-alpha (adverse effects)</term><term>Interferon-alpha (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nausea (epidemiology)</term><term>Oligopeptides (administration & dosage)</term><term>Oligopeptides (adverse effects)</term><term>Oligopeptides (therapeutic use)</term><term>Polyethylene Glycols (adverse effects)</term><term>Polyethylene Glycols (therapeutic use)</term><term>RNA, Viral (blood)</term><term>Recombinant Proteins (adverse effects)</term><term>Recombinant Proteins (therapeutic use)</term><term>Ribavirin (adverse effects)</term><term>Ribavirin (therapeutic use)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (sang)</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Céphalée (épidémiologie)</term><term>Fatigue (épidémiologie)</term><term>Femelle</term><term>Génotype</term><term>Hepacivirus (génétique)</term><term>Humains</term><term>Hépatite C chronique (sang)</term><term>Hépatite C chronique (traitement médicamenteux)</term><term>Incidence</term><term>Interféron alpha (effets indésirables)</term><term>Interféron alpha (usage thérapeutique)</term><term>Mâle</term><term>Nausée (épidémiologie)</term><term>Oligopeptides (administration et posologie)</term><term>Oligopeptides (effets indésirables)</term><term>Oligopeptides (usage thérapeutique)</term><term>Polyéthylène glycols (effets indésirables)</term><term>Polyéthylène glycols (usage thérapeutique)</term><term>Protéines recombinantes (effets indésirables)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Relation dose-effet des médicaments</term><term>Ribavirine (effets indésirables)</term><term>Ribavirine (usage thérapeutique)</term><term>Résultat thérapeutique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Oligopeptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Oligopeptides</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Oligopeptides</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Oligopeptides</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Oligopeptides</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Fatigue</term><term>Headache</term><term>Nausea</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>ARN viral</term><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite C chronique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term><term>Oligopeptides</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Céphalée</term><term>Fatigue</term><term>Nausée</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Génotype</term><term>Humains</term><term>Incidence</term><term>Mâle</term><term>Relation dose-effet des médicaments</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We performed an open-label, multicenter, phase 3 study of the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>Brésil</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pologne</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Bahia</li><li>Californie</li><li>Catalogne</li><li>District de Darmstadt</li><li>Hesse (Land)</li><li>New Jersey</li><li>Piémont</li><li>Région de Bruxelles-Capitale</li><li>Victoria (État)</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Barcelone</li><li>Bruxelles</li><li>Créteil</li><li>Francfort-sur-le-Main</li><li>Melbourne</li><li>Turin</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Buti, Maria" sort="Buti, Maria" uniqKey="Buti M" first="Maria" last="Buti">Maria Buti</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Agarwal, Kosh" sort="Agarwal, Kosh" uniqKey="Agarwal K" first="Kosh" last="Agarwal">Kosh Agarwal</name></region></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Horsmans, Yves" sort="Horsmans, Yves" uniqKey="Horsmans Y" first="Yves" last="Horsmans">Yves Horsmans</name></region><name sortKey="De Meyer, Sandra" sort="De Meyer, Sandra" uniqKey="De Meyer S" first="Sandra" last="De Meyer">Sandra De Meyer</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Sievert, William" sort="Sievert, William" uniqKey="Sievert W" first="William" last="Sievert">William Sievert</name></region></country><country name="Pologne"><noRegion><name sortKey="Janczewska, Ewa" sort="Janczewska, Ewa" uniqKey="Janczewska E" first="Ewa" last="Janczewska">Ewa Janczewska</name></noRegion></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name></region></country><country name="États-Unis"><region name="Californie"><name sortKey="Nyberg, Lisa" sort="Nyberg, Lisa" uniqKey="Nyberg L" first="Lisa" last="Nyberg">Lisa Nyberg</name></region><name sortKey="Bertelsen, Kirk" sort="Bertelsen, Kirk" uniqKey="Bertelsen K" first="Kirk" last="Bertelsen">Kirk Bertelsen</name><name sortKey="Brown, Robert S" sort="Brown, Robert S" uniqKey="Brown R" first="Robert S" last="Brown">Robert S. Brown</name><name sortKey="De Masi, Ralph" sort="De Masi, Ralph" uniqKey="De Masi R" first="Ralph" last="De Masi">Ralph De Masi</name><name sortKey="Luo, Donghan" sort="Luo, Donghan" uniqKey="Luo D" first="Donghan" last="Luo">Donghan Luo</name><name sortKey="Witek, James" sort="Witek, James" uniqKey="Witek J" first="James" last="Witek">James Witek</name></country><country name="France"><region name="Île-de-France"><name sortKey="Hezode, Christophe" sort="Hezode, Christophe" uniqKey="Hezode C" first="Christophe" last="Hézode">Christophe Hézode</name></region></country><country name="Italie"><region name="Piémont"><name sortKey="Rizzetto, Mario" sort="Rizzetto, Mario" uniqKey="Rizzetto M" first="Mario" last="Rizzetto">Mario Rizzetto</name></region></country><country name="Brésil"><region name="Bahia"><name sortKey="Parana, Raymundo" sort="Parana, Raymundo" uniqKey="Parana R" first="Raymundo" last="Paraná">Raymundo Paraná</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003477 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003477 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24316262
|texte= Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24316262" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |